Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.

MLA

Plimack, Elizabeth R., et al. “Pembrolizumab Plus Axitinib Versus Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma: 43-Month Follow-up of the Phase 3 KEYNOTE-426 Study.” European Urology, vol. 84, no. 5, Nov. 2023, pp. 449–54. EBSCOhost, https://doi.org/10.1016/j.eururo.2023.06.006.

APA

Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., Alekseev, B., Pouliot, F., Melichar, B., Soulières, D., Borchiellini, D., McDermott, R. S., Vynnychenko, I., Chang, Y.-H., Tamada, S., Atkins, M. B., Li, C., Perini, R., Molife, L. R., & Bedke, J. (2023). Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study. European Urology, 84(5), 449–454. https://doi.org/10.1016/j.eururo.2023.06.006

Chicago

Plimack, Elizabeth R., Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, et al. 2023. “Pembrolizumab Plus Axitinib Versus Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma: 43-Month Follow-up of the Phase 3 KEYNOTE-426 Study.” European Urology 84 (5): 449–54. doi:10.1016/j.eururo.2023.06.006.